Freitag, 3. Mai 2024
Navigation öffnen
Anzeige:
Wefra Programatic
 
JOURNAL ONKOLOGIE – STUDIE

Assessment of Histologic Prognostic Factors in Peritoneal Malignant Mesothelioma

Rekrutierend

NCT-Nummer:
NCT05193006

Studienbeginn:
Dezember 2021

Letztes Update:
14.01.2022

Wirkstoff:
-

Indikation (Clinical Trials):
Mesothelioma, Mesothelioma, Malignant, Lung Neoplasms

Geschlecht:
Alle

Altersgruppe:
Erwachsene (18+)

Phase:
-

Sponsor:
Hospices Civils de Lyon

Collaborator:
-

Studienlocations
(3 von 6)

Institut f. Pathologie und Neuropathologie
72076 Tübingen
(Baden-Württemberg)
GermanyRekrutierend» Google-Maps
Ansprechpartner:
Wiebke Solass Wiebke Solass, MD
Phone: 07071 29-82270
E-Mail: Wiebke.Solass@med.uni-tuebingen.de» Ansprechpartner anzeigen
Fundação Champalimaud
1400-038 Lisboa
PortugalRekrutierend» Google-Maps
Ansprechpartner:
Mireia Castillo-Martin Mireia Castillo-Martin, MD
Phone: +351) 210480048
E-Mail: mireia.castillo@fundacaochampalimaud.pt» Ansprechpartner anzeigen
Alle anzeigen

Studien-Informationen

Brief Summary:

Malignant peritoneal mesothelioma is a rare neoplasm. The most common type, the epithelioid

type, has been further divided into histological patterns of tubulo-papillary, acinar,

adenomatoid, micropapillary, or solid. Its prognosis is improved by the use of a locoregional

treatment combining extensive cytoreductive surgery (CRS) and hyperthermic intraperitoneal

chemotherapy (HIPEC), which increases survival up to 50 months. Histology is one of the most

important prognostic variable that, forms the basis for treatment decisions. However, the

prognostic of the epithelioid type varies greatly due to its tumor heterogeneity. It is

therefore necessary to find prognostic factors of malignant epithelioid peritoneal

mesothelioma in order to better define the therapeutic strategy. Among histological factors,

solid growth, tumor necrosis, nuclear atypia, and mitotic count were found to be independent

prognostic factors in epithelioid malignant pleural mesothelioma. However, in epithelioid

malignant peritoneal mesothelioma (EMPM), these factors were studied in small and

heterogeneous series in terms of histological growth and definitions used for histological

factors. The present large study was conducted to investigate the prognostic impact of

several histologic factors in EMPM. Their prognosis impacts were assessed using overall

survival (OS) and progression-free survival (PFS) in EMPM.

Ein-/Ausschlusskriterien

Inclusion Criteria:

- - peritoneal malignant mesothelioma

Exclusion Criteria:

- opposition to reuse personnal data

Studien-Rationale

Primary outcome:

1. Assessment of pronostic impact of nuclear grade in comparison with combined grade in peritoneal malignant mesothelioma (Time Frame - 3 months to 4 years):
Assessment by the review of pathologists

Studien-Arme

  • peritoneal malignant mesothelioma of grade 1
    peritoneal malignant mesothelioma of grade 1
  • peritoneal malignant mesothelioma of grade 2
    peritoneal malignant mesothelioma of grade 2
  • peritoneal malignant mesothelioma of grade 3
    peritoneal malignant mesothelioma of grade 3

Geprüfte Regime

  • No intervention:
    No intervention

Quelle: ClinicalTrials.gov


Sie können folgenden Inhalt einem Kollegen empfehlen:

"Assessment of Histologic Prognostic Factors in Peritoneal Malignant Mesothelioma"

Bitte tragen Sie auch die Absenderdaten vollständig ein, damit Sie der Empfänger erkennen kann.

Die mit (*) gekennzeichneten Angaben müssen eingetragen werden!

Die Verwendung Ihrer Daten für den Newsletter können Sie jederzeit mit Wirkung für die Zukunft gegenüber der MedtriX GmbH - Geschäftsbereich rs media widersprechen ohne dass Kosten entstehen. Nutzen Sie hierfür etwaige Abmeldelinks im Newsletter oder schreiben Sie eine E-Mail an: rgb-info[at]medtrix.group.